Hemophilia A is an X-linked bleeding disorder caused by the deficiency of factor VIII (FVIII). Exogenous FVIII is administered therapeutically, and due to a short half-life, frequent infusions are often required. Fifteen to thirty-five percent of severe hemophilia A patients develop inhibitory antibodies toward FVIII that complicate clinical management of the disease.
PEGylation of a Factor VIII-phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice
3월 1, 2012
Author(s):
Year: